clarithromycin has been researched along with sparfloxacin in 33 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (51.52) | 18.2507 |
| 2000's | 13 (39.39) | 29.6817 |
| 2010's | 3 (9.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirayama, F; Ikeda, Y; Kawakita, T; Kuroda, T; Moriguchi, A; Sakurai, N; Sano, M; Uemori, S; Yamamoto, K | 1 |
| Keserü, GM | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Cui, L; Hiramatsu, K; Neoh, HM; Shoji, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Grosset, JH; Ji, B; Perani, EG; Petinon, C | 1 |
| Chehl, SK; Gelber, RH; Murray, LP; Richard, V; Siu, P; Tsang, M | 1 |
| Dekio, S; Hidaka, T; Kawahara, S; Saito, H; Sato, K; Tomioka, H | 1 |
| Courdil, M; Escaffre, MC; Lareng, MB; Lefèvre, JC | 1 |
| Citron, DM; Goldstein, EJ | 1 |
| Bourgeois, P; Cambau, E; Desplaces, N; Dion, E; Dubourg, G; Koeger, AC; Robin, H; Roche, B; Rozenberg, S; Vergeron, H | 1 |
| Davies, BI; Dirks-Go, SI; Hoogkamp-Korstanje, JA; Kabel, P; Manson, WL; Stobberingh, EE; Vreede, RW | 1 |
| Andrews, JM; Boswell, F; Brenwald, NP; Wise, R | 1 |
| Barbeau, P; Lapeyre, C; Leng, B; Maugein, J; Pellegrin, I; Pellegrin, JL | 1 |
| Horgen, L; Legrand, E; Rastogi, N | 1 |
| Ramirez, J; Talbot, GH; Townsend, L; Unowsky, J; Zhang, H | 1 |
| Adelglass, J; Henry, DC; Jablonski, CK; Moller, DJ; Scheld, WM; Talbot, GH; Zhang, H | 1 |
| Appelbaum, PC; Hoellman, DB; Jacobs, MR; Lin, G | 1 |
| Higashiyama, Y; Kohno, S; Maesaki, S; Miyazaki, Y; Tashiro, T; Tomiyama, Y; Tomono, K; Yong, B | 1 |
| Adam, G; Haase, G; Riehl, J; Schmitt, H; Schnitzler, N; Sieberth, HG | 1 |
| Lipsky, BA; Talbot, GH; Townsend, L; Unowsky, J; Zhang, H | 1 |
| Goss, TF; Najib, MM; Stein, GE | 1 |
| Matsumoto, A; Matsushima, T; Miyashita, N | 1 |
| Hashido, H; Ishigo, S; Iwata, I; Matsubara, S; Matsukawa, Y; Mikamo, H; Sawamura, H; Suematsu, H; Tamaya, T | 1 |
| Kashiwabara, Y; Matsuoka, M; Namisato, M | 1 |
| Bentoucha, A; Dega, H; Grosset, J; Jarlier, V; Robert, J | 1 |
| Kai, Y; Kuroki, M; Matsuyama, M; Murai, K; Nagatomo, Y; Okayama, A; Sasaki, T; Tanaka, G; Tsubouchi, H | 1 |
| Katouno, Y; Kobayashi, Y; Sugita, K; Uchida, H | 1 |
3 trial(s) available for clarithromycin and sparfloxacin
| Article | Year |
|---|---|
Sparfloxacin versus clarithromycin in the treatment of community-acquired pneumonia.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Community-Acquired Infections; Double-Blind Method; Female; Fluoroquinolones; Humans; Male; Middle Aged; Pneumonia, Bacterial; Quinolones | 1999 |
Comparison of sparfloxacin and clarithromycin in the treatment of acute bacterial maxillary sinusitis. Sparfloxacin Multicenter AMS Study Group.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Infections; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Female; Fluoroquinolones; Humans; Male; Maxillary Sinusitis | 1999 |
Treating acute bacterial exacerbations of chronic bronchitis in patients unresponsive to previous therapy: sparfloxacin versus clarithromycin.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Bronchitis; Chronic Disease; Clarithromycin; Double-Blind Method; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Male; Middle Aged | 1999 |
30 other study(ies) available for clarithromycin and sparfloxacin
| Article | Year |
|---|---|
Synthesis and structure-activity relationships of 7-(2-aminoalkyl)morpholinoquinolones as anti-Helicobacter pylori agents.
Topics: 4-Quinolones; Animals; Anti-Infective Agents; Drug Stability; Fluoroquinolones; Gerbillinae; Helicobacter Infections; Helicobacter pylori; Indicators and Reagents; Microbial Sensitivity Tests; Molecular Structure; Naphthyridines; Ofloxacin; Quinolones; Solutions; Structure-Activity Relationship; Ultraviolet Rays | 1998 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; Chromosome Walking; DNA-Binding Proteins; Genetic Engineering; Genome, Bacterial; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Point Mutation; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Staphylococcus aureus; Vancomycin; Vancomycin Resistance | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Bactericidal activities of single or multiple doses of various combinations of new antileprosy drugs and/or rifampin against M. leprae in mice.
Topics: Animals; Clarithromycin; Disease Models, Animal; Female; Fluoroquinolones; Foot; Hindlimb; Immunocompetence; Leprostatic Agents; Leprosy; Mice; Microbial Sensitivity Tests; Minocycline; Mycobacterium leprae; Ofloxacin; Quinolones; Rifampin | 1992 |
Activity of combinations of dapsone, rifampin, minocycline, clarithromycin, and sparfloxacin against M. leprae-infected mice.
Topics: Animals; Anti-Infective Agents; Clarithromycin; Dapsone; Drug Therapy, Combination; Female; Fluoroquinolones; Leprosy; Mice; Mice, Inbred BALB C; Minocycline; Quinolones; Rifampin | 1995 |
Therapeutic effect of KRM-1648 with various antimicrobials against Mycobacterium avium complex infection in mice.
Topics: Animals; Antitubercular Agents; Clarithromycin; Clofazimine; Drug Synergism; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Microbial Sensitivity Tests; Mycobacterium avium-intracellulare Infection; Ofloxacin; Quinolones; Rifamycins; Streptomycin | 1995 |
In vitro evaluation of activities of azithromycin, clarithromycin and sparfloxacin against Chlamydia trachomatis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Chlamydia trachomatis; Clarithromycin; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; In Vitro Techniques; Quinolones | 1993 |
Comparative susceptibilities of 173 aerobic and anaerobic bite wound isolates to sparfloxacin, temafloxacin, clarithromycin, and older agents.
Topics: Animals; Anti-Bacterial Agents; Bacteria, Aerobic; Bacteria, Anaerobic; Bites and Stings; Clarithromycin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Quinolones; Wound Infection | 1993 |
Efficacy of combined clarithromycin and sparfloxacin therapy in a patient with discitis: due to Mycobacterium xenopi.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Discitis; Drug Therapy, Combination; Fluoroquinolones; Humans; Lumbar Vertebrae; Male; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Quinolones; Sacrum | 1997 |
Multicentre in-vitro evaluation of the susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis to ciprofloxacin, clarithromycin, co-amoxiclav and sparfloxacin.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Ciprofloxacin; Clarithromycin; Clavulanic Acids; Drug Evaluation; Drug Therapy, Combination; Fluoroquinolones; Haemophilus influenzae; Microbial Sensitivity Tests; Moraxella catarrhalis; Quinolones; Streptococcus pneumoniae | 1997 |
The activity of the methylpiperazinyl fluoroquinolone CG 5501: a comparison with other fluoroquinolones.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Bacteroides fragilis; Chlamydia; Ciprofloxacin; Clarithromycin; Doxycycline; Enterobacter; Erythromycin; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Haemophilus influenzae; Microbial Sensitivity Tests; Naphthyridines; Piperazines; Pseudomonas aeruginosa; Quinolones; Streptococcus pneumoniae | 1997 |
Activity of rifabutin, clarithromycin, ethambutol, sparfloxacin and amikacin, alone and in combination, against Mycobacterium avium complex in human macrophages.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Clarithromycin; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Macrophages; Microbial Sensitivity Tests; Mycobacterium avium Complex; Mycobacterium avium-intracellulare Infection; Quinolones; Rifabutin | 1996 |
Postantibiotic effect of amikacin, rifampin, sparfloxacin, clofazimine and clarithromycin against Mycobacterium avium.
Topics: Amikacin; Anti-Bacterial Agents; Bacteriological Techniques; Clarithromycin; Clofazimine; Colony Count, Microbial; Fluoroquinolones; Humans; Mycobacterium avium Complex; Quinolones; Rifampin; Serum Bactericidal Test | 1997 |
Anti-pneumococcal activity of gatifloxacin compared with other quinolone and non-quinolone agents.
Topics: Amoxicillin; Anti-Infective Agents; Ceftriaxone; Cefuroxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Naphthyridines; Ofloxacin; Penicillin Resistance; Streptococcus pneumoniae | 1999 |
[The combination therapy of clarithromycin and sparfloxacin for pulmonary Mycobacterium gordonae infection].
Topics: Aged; Anti-Infective Agents; Antitubercular Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Pneumonia, Bacterial; Treatment Outcome | 1999 |
Successful treatment of pulmonary Mycobacterium xenopi infection in a natural killer cell-deficient patient with clarithromycin, rifabutin, and sparfloxacin.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Antitubercular Agents; Clarithromycin; Drug Therapy, Combination; Fluoroquinolones; Humans; Killer Cells, Natural; Lung; Male; Mycobacterium Infections, Nontuberculous; Mycobacterium xenopi; Rifabutin; Treatment Outcome; Tuberculosis, Pulmonary | 1999 |
Cost-effectiveness of sparfloxacin compared with other oral antimicrobials in outpatient treatment of community-acquired pneumonia.
Topics: Administration, Oral; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Antitubercular Agents; Azithromycin; Cefaclor; Clarithromycin; Community-Acquired Infections; Cost-Benefit Analysis; Erythromycin; Fluoroquinolones; Humans; Models, Economic; Outpatients; Pneumonia; Treatment Outcome | 2000 |
In vitro susceptibility of 7.5-kb common plasmid-free Chlamydia trachomatis strains.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Chlamydia Infections; Chlamydia trachomatis; Clarithromycin; Drug Resistance, Microbial; Erythromycin; Fluoroquinolones; Glycogen; Humans; Male; Microbial Sensitivity Tests; Minocycline; Ofloxacin; Plasmids; Urethritis | 2000 |
[The frequency of Streptococcus pneumoniae strains and sensitivity surveillance for several antibiotics in Gifu Prefecture].
Topics: Amoxicillin; Anti-Bacterial Agents; Cefaclor; Cefdinir; Cefixime; Cefmenoxime; Cefpodoxime; Ceftizoxime; Cephalosporins; Ciprofloxacin; Clarithromycin; Clindamycin; Drug Resistance, Microbial; Fluoroquinolones; Humans; Imipenem; Japan; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Minocycline; Naphthyridines; Ofloxacin; Penicillin G; Penicillins; Streptococcus pneumoniae; Thienamycins | 2000 |
A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
Topics: Animals; Anti-Infective Agents; Antitubercular Agents; Clarithromycin; Clofazimine; Colony Count, Microbial; Dapsone; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Leprostatic Agents; Leprosy; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Mycobacterium leprae; Ofloxacin; Rifampin | 2000 |
Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Clarithromycin; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Foot; Mice; Mice, Inbred BALB C; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Rifampin; Skin Ulcer | 2002 |
[Mycoplasma pneumonia of identical twin sisters with different clinical courses depending on the treatment].
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Diseases in Twins; Female; Fluoroquinolones; Humans; Methylprednisolone; Pneumonia, Mycoplasma | 2002 |
[Comparative in vitro activities of several antimicrobial agents against Helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Gastric Mucosa; Helicobacter pylori; Humans; Levofloxacin; Microbial Sensitivity Tests; Norfloxacin; Ofloxacin; Penicillins; Stomach Ulcer | 2002 |